B+
Bull case
20%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-06-10 · RankAlpha Sentiment Codex
CGEM
Cullinan TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Cullinan has multiple near-term binary value catalysts: CLN-978 autoimmune readouts, zipalertinib's FDA review, and CLN-049/velinotamig follow-through. Q1 also showed $393.3m cash/investments and runway into 2029, reducing financing pressure, while the June 8 8-K's improvement in disease-activity labs gives the autoimmune program a positive early read [#PR-EARNINGS-2026-05-07] [#SEC-8K-2026-05-07] [#8-K-2026-06-08].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.0.
What can break
CLN-049 remains early-stage and needs more data before a registrational path is credible; tolerability or efficacy could fall short.
Momentum
92
Value
41
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.50 · Bull $30.00 · Bear $6.50Analysis 2026-06-10; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-10 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $33.67
Why
Momentum92 · Δ7d +1.8
Value41 · Δ7d -0.0
Sentiment22 · Δ7d +1.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +1.0.
Contradictions & invalidation
- • CLN-049 remains early-stage and needs more data before a registrational path is credible; tolerability or efficacy could fall short.
- • CLN-978 may not sustain the early biomarker or clinical activity signal across the upcoming June/Q3/Q4 readouts, which would pressure the autoimmune thesis.
- • The stock is still a pre-commercial biotech where value depends on early clinical and regulatory outcomes.
Catalyst clock
2026-06-06
CLN-978 initial SLE/RA data and biomarker follow-through
Lead driver: Sentiment · See AI snapshot
Momentum
92
9% active weight
Current posture
7d trendFlat
Δ7d
+1.8
Δ21d
+3.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
22
62% active weight
Current posture
7d trendImproving
Δ7d
+1.0
Δ21d
-6.0
Why this grade
Composite grade F. Momentum 92.2 / Value 41.2 / Sentiment 22.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-10. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-06-10 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-06-10 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.33B
Beta
-0.09
Shares Out
64.56M
P/E (TTM) · Derived
-5.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.94
Rev YoY
-100.0%
EPS YoY
-27.0%
Gross Margin
-
Op Margin
-
Net Debt
-$375.21M
Current Ratio
8.42
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data